Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Registration Statement · S-1

Propanc Biopharma, Inc.

PPCBNASDAQEQUITYCurrent

Registration Statement

Filed Feb 2, 2026Accepted Feb 2, 2026, 5:29 PM ESTCIK 1517681Accession 0001493152-26-004792
Share

Company context

We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.

Current securities

Recent company filings

  1. 10-K filingSep 25, 2026
  2. DEF 14C filingAug 21, 2026
  3. PRE 14C filingAug 5, 2026
  4. EFFECT filingJul 27, 2026
  5. S-1 filingJul 17, 2026

As-filed source

Primary evidence